Breast-Cancer Pill to Get Priority FDA Review
17th Nov 2006, 08:03 GMT
GlaxoSmithKline said its new breast-cancer pill, Tykerb, will receive a priority review from the FDA.
Latest news from WSJ.com: What's News Europe:
- Deutsche Telekom CEO Resigns
- European Shares Gain Ground
- Arcelor Mittal Says Dofasco Sale Is Thwarted
- U.K. Life-Insurance Market May Shrink
- Two Italian Banks Discuss Merger
- FDA Extends Novartis Drug Review
- European Shares Gain Ground
- Qualcomm, Nokia Deal Is Unlikely
- BPU Board Backs Purchase of Rival
- Marshall Wace Plans Hedge-Fund IPO